2H23 Pharma/Biotech Outlook (Part. 1)
We are now at the end of the tumultuous first half of the year. We still have a week remaining as of today, but as investors, we are always forward-looking.…
Thoughts on LLY for 1Q23, 2023, and beyond
Eli Lilly stock has been on a tear over the last five years - appreciating by +200% during that time. That is something that you generally would not expect from…
4Q22 Biotech / Pharma investing outlook – negative overall, but some bright spots
We are now just in front of 4Q22 at mid-September. 3Q22 saw great inflection for biotech after big drawdown in 2Q - many investors were caught off guard with this…
Lesson from my PM: Don’t short against management’s bullish tone / hype
I am very lucky in that I met a portfolio manager that cares about my development as an investor. I feel comfortable to share my thoughts freely and as a…
Story of Alexion – High barrier to entry drugs provide predictable and compounding growth
Unlike consumer or industrials sectors, biotechnology is very different in that while scale of economies or network effects often serve as the barriers to entry for consumer or industrials companies,…